INVENTIVA ADS/1 O.N. (6IVA) - Total Assets
Based on the latest financial reports, INVENTIVA ADS/1 O.N. (6IVA) holds total assets worth €249.51 Million EUR (≈ $291.70 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 6IVA total equity for net asset value and shareholders' equity analysis.
INVENTIVA ADS/1 O.N. - Total Assets Trend (2021–2025)
This chart illustrates how INVENTIVA ADS/1 O.N.'s total assets have evolved over time, based on quarterly financial data.
INVENTIVA ADS/1 O.N. - Asset Composition Analysis
Current Asset Composition (December 2025)
INVENTIVA ADS/1 O.N.'s total assets of €249.51 Million consist of 98.0% current assets and 2.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 39.8% |
| Accounts Receivable | €2.02 Million | 0.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €183.00K | 0.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how INVENTIVA ADS/1 O.N.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is INVENTIVA ADS/1 O.N. worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INVENTIVA ADS/1 O.N.'s current assets represent 98.0% of total assets in 2025, an increase from 94.8% in 2021.
- Cash Position: Cash and equivalents constituted 39.8% of total assets in 2025, down from 71.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
INVENTIVA ADS/1 O.N. Competitors by Total Assets
Key competitors of INVENTIVA ADS/1 O.N. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.76 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
INVENTIVA ADS/1 O.N. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.16 | 0.92 | 0.59 |
| Quick Ratio | 3.16 | 0.92 | 0.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €167.09 Million | €-9.22 Million | €-19.54 Million |
INVENTIVA ADS/1 O.N. - Advanced Valuation Insights
This section examines the relationship between INVENTIVA ADS/1 O.N.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.02 |
| Latest Market Cap to Assets Ratio | 3.84 |
| Asset Growth Rate (YoY) | 109.7% |
| Total Assets | €249.51 Million |
| Market Capitalization | $957.19 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values INVENTIVA ADS/1 O.N.'s assets at a significant premium (3.84x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: INVENTIVA ADS/1 O.N.'s assets grew by 109.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for INVENTIVA ADS/1 O.N. (2021–2025)
The table below shows the annual total assets of INVENTIVA ADS/1 O.N. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €249.51 Million ≈ $291.70 Million |
+109.73% |
| 2024-12-31 | €118.97 Million ≈ $139.08 Million |
+71.03% |
| 2023-12-31 | €69.56 Million ≈ $81.32 Million |
-40.04% |
| 2022-12-31 | €116.00 Million ≈ $135.62 Million |
-4.90% |
| 2021-12-31 | €121.98 Million ≈ $142.61 Million |
-- |
About INVENTIVA ADS/1 O.N.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more